scholarly journals Analysis of copy number alterations reveals the lncRNA ALAL-1 as a regulator of lung cancer immune evasion

2020 ◽  
Vol 219 (9) ◽  
Author(s):  
Alejandro Athie ◽  
Francesco P. Marchese ◽  
Jovanna González ◽  
Teresa Lozano ◽  
Ivan Raimondi ◽  
...  

Cancer is characterized by genomic instability leading to deletion or amplification of oncogenes or tumor suppressors. However, most of the altered regions are devoid of known cancer drivers. Here, we identify lncRNAs frequently lost or amplified in cancer. Among them, we found amplified lncRNA associated with lung cancer-1 (ALAL-1) as frequently amplified in lung adenocarcinomas. ALAL-1 is also overexpressed in additional tumor types, such as lung squamous carcinoma. The RNA product of ALAL-1 is able to promote the proliferation and tumorigenicity of lung cancer cells. ALAL-1 is a TNFα− and NF-κB–induced cytoplasmic lncRNA that specifically interacts with SART3, regulating the subcellular localization of the protein deubiquitinase USP4 and, in turn, its function in the cell. Interestingly, ALAL-1 expression inversely correlates with the immune infiltration of lung squamous tumors, while tumors with ALAL-1 amplification show lower infiltration of several types of immune cells. We have thus unveiled a pro-oncogenic lncRNA that mediates cancer immune evasion, pointing to a new target for immune potentiation.

2020 ◽  
Author(s):  
Yadong Gao ◽  
Jianwei Qiu ◽  
Liugen Gu ◽  
Yanmei Yang ◽  
Haifeng Kang ◽  
...  

Abstract Background: The present study aimed to assess the incidence, characteristics, and survival of secondary primary lung cancer after primary esophageal cancer (EC-LC). Methods: The patients with esophageal cancer (EC) who developed SPLC and patients with first primary lung cancer (LC-1) were retrospectively reviewed in the Surveillance, Epidemiology, and End Results 18 registries covering 2000 to 2016. The risk of secondary primary lung cancer using standardized incidence ratio (SIR) was calculated among patients with EC. Overall survival and characteristics were compared between patients with EC-LC and patients with LC-1.Results: In comparison with the general population, the patients with EC had a higher risk for developing secondary primary lung cancer (SIR =1.86, 95% confidence interval (CI): 1.69-2.05). There was a significant difference with regard to the year of diagnosis, sex, grade and stage between the secondary primary lung squamous carcinoma after EC (EC-LUSC) and first primary lung squamous carcinoma (LUSC-1) patients. A statistically significant difference with respect to race, sex, age, year, grade and stage was found between the secondary primary lung adenocarcinoma after EC (EC-LUAD) and first primary lung adenocarcinoma (LUAD-1) patients. A history of EC was found to be an independent risk factor of death for lung squamous carcinoma and lung adenocarcinoma patients in localized stage based on multivariate Cox regression analysis, propensity score-matching analysis and multiple imputation.Conclusion: There is a significantly increased risk of secondary primary lung cancer in EC survivors and a history of EC adversely affects overall survival in individuals who subsequently develop localized EC-LUSC and EC-LUAD. Clinicians should moderately strengthen lung tissue protection during the management of EC patients.


PLoS ONE ◽  
2014 ◽  
Vol 9 (2) ◽  
pp. e88300 ◽  
Author(s):  
Bi-Qing Li ◽  
Jin You ◽  
Tao Huang ◽  
Yu-Dong Cai

2017 ◽  
Vol Volume 10 ◽  
pp. 4969-4979 ◽  
Author(s):  
Ann-Louise Vikberg ◽  
Tõnu Vooder ◽  
Kaie Lokk ◽  
Tarmo Annilo ◽  
Irina Golovleva

2019 ◽  
Vol 14 (5) ◽  
pp. 876-889 ◽  
Author(s):  
Badi El Osta ◽  
Madhusmita Behera ◽  
Sungjin Kim ◽  
Lynne D. Berry ◽  
Gabriel Sica ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document